KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Cash from Investing Activities: 2009-2025

Historic Cash from Investing Activities for Ionis Pharmaceuticals (IONS) over the last 16 years, with Sep 2025 value amounting to $91.3 million.

  • Ionis Pharmaceuticals' Cash from Investing Activities rose 126.80% to $91.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $209.9 million, marking a year-over-year increase of 191.70%. This contributed to the annual value of -$134.0 million for FY2024, which is 37.41% up from last year.
  • Ionis Pharmaceuticals' Cash from Investing Activities amounted to $91.3 million in Q3 2025, which was up 176.07% from -$120.1 million recorded in Q2 2025.
  • In the past 5 years, Ionis Pharmaceuticals' Cash from Investing Activities ranged from a high of $212.1 million in Q4 2022 and a low of -$340.8 million during Q3 2024.
  • In the last 3 years, Ionis Pharmaceuticals' Cash from Investing Activities had a median value of $68.2 million in 2024 and averaged -$18.8 million.
  • As far as peak fluctuations go, Ionis Pharmaceuticals' Cash from Investing Activities spiked by 2,203.96% in 2023, and later tumbled by 595.98% in 2024.
  • Over the past 5 years, Ionis Pharmaceuticals' Cash from Investing Activities (Quarterly) stood at $95.1 million in 2021, then skyrocketed by 123.06% to $212.1 million in 2022, then slumped by 112.59% to -$26.7 million in 2023, then skyrocketed by 355.36% to $68.2 million in 2024, then surged by 126.80% to $91.3 million in 2025.
  • Its Cash from Investing Activities was $91.3 million in Q3 2025, compared to -$120.1 million in Q2 2025 and $170.5 million in Q1 2025.